Latest / Pharmacy Podcast Network / Navigating the Next Wave: CEO Insights on Pharma’s Future | Executive Dose
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:28Speaker 2: Welcome to Executive Dose, the podcast where pharmaceutical leadership meets
- 0:33Speaker 2: unfiltered insight. Hosted by Stephen Beckman, CEO of Your All Pharma,
- 0:38Speaker 2: Each episode explores the complex forces shaping today's pharmaceutical industry,
- 0:43Speaker 2: from global supply chain stress and regulatory shakeups to innovation
- 0:47Speaker 2: in branded and generic drug markets. Join us as we
- 0:50Speaker 2: engage sea level leaders and decision makers in candid conversations
- 0:53Speaker 2: about navigating disruption, driving growth, and preparing for the next
- 0:57Speaker 2: era of pharmaceutical transformation. Leads strategy follows. This is the
- 1:02Speaker 2: Executive Dose.
- 1:08Speaker 3: Hey, this is the Executive Dose podcast, part of the
- 1:12Speaker 3: Pharmacy Podcast Network. I'm the founder of the PPN. My
- 1:16Speaker 3: name is Todd Yuriy. We started this in two thousand
- 1:19Speaker 3: and nine, the first podcast about our pharmacy profession. As
- 1:22Speaker 3: we have evolved, we realize that there's always these gaps
- 1:27Speaker 3: in the content that we're delivering to over eighty thousand
- 1:30Speaker 3: listeners per month, and one of those gaps is digging
- 1:33Speaker 3: deeper into the pharmaceutical sector. In the support that that
- 1:37Speaker 3: part of the industry gives all of healthcare and how
- 1:40Speaker 3: that's connected directly to our pharmacist, my favorite provider. We
- 1:44Speaker 3: have someone who is special to me, a friend of mine,
- 1:48Speaker 3: lives in Brownsville, Pennsylvania, the studio headquarters of the Pharmacy
- 1:51Speaker 3: Podcast Network. I met him in San Diego at the
- 1:55Speaker 3: NACDS Total Store Expo and I want to say, welcome
- 1:58Speaker 3: to your own show, mister Steven Beckman.
- 2:01Speaker 4: Well, thanks, Todd, and it's a pleasure to be here.
- 2:04Speaker 4: I couldn't agree with you more. This whole concept is
- 2:07Speaker 4: about exchange of information and a greater and deeper understanding
- 2:12Speaker 4: of how all the players have an impact in delivering
- 2:16Speaker 4: health care to our patients. And I think a lot
- 2:19Speaker 4: of times people interpret the same things that we're seeing
- 2:22Speaker 4: differently or assume certain things of how we operate as manufacturers.
- 2:28Speaker 4: And we thought this what a great podcast is to
- 2:31Speaker 4: be able to start showing how all the things that
- 2:34Speaker 4: are impacting us do actually impact all of us in
- 2:37Speaker 4: different ways, and how we can ultimately work together and
- 2:40Speaker 4: with a greater understanding. I think it's going to open
- 2:43Speaker 4: the doors to find better ways to work with each other,
- 2:46Speaker 4: support each other, and ultimately improve the outcome the patients,
- 2:50Speaker 4: which is why whether you're a pharmacist or a CEO
- 2:53Speaker 4: of a manufacturing company and everybody in between, I think
- 2:56Speaker 4: we get into this industry because we have a passion
- 2:59Speaker 4: to helping pay and people in need, and that's what
- 3:01Speaker 4: we really want to do. So obviously we're looking to
- 3:04Speaker 4: be focus on timely topics and issues and translate that
- 3:10Speaker 4: into a discussion that will allow us to see how
- 3:13Speaker 4: that's really impacting us in a very open and honest way.
- 3:15Speaker 4: So I think, if I'm not mistaken, Todd, you actually
- 3:19Speaker 4: caught a headline this morning that you wanted to put
- 3:22Speaker 4: up on the screen.
- 3:23Speaker 3: Yeah, I'm telling you what, Just for the listeners, this
- 3:26Speaker 3: article that just came out, Big Pharma likely to endure
- 3:30Speaker 3: Trump's tariff pricing pressures, but threats to generics persist. And Stephen,
- 3:37Speaker 3: this is why I'm glad you're here, because we're going
- 3:39Speaker 3: to be able to tap into your understanding of the
- 3:42Speaker 3: pharmaceutical markets as our expert.
- 3:44Speaker 4: Every single one of our.
- 3:45Speaker 3: Hosts always drill down into their specific theme and that's
- 3:49Speaker 3: why the executive dose, that's why we're excited to have
- 3:52Speaker 3: you here. So kicking right off. You have a guest
- 3:55Speaker 3: that actually can help kind of blow this up even
- 3:58Speaker 3: more so, so definitely do some to us.
- 4:01Speaker 4: Yeah, so I'd like to introduce Nick Hart, the CEO
- 4:04Speaker 4: of IPSA USA, is one of the companies within the
- 4:08Speaker 4: Ipsch family where Uryle also sits. So it's great to
- 4:12Speaker 4: have you, Nick. I appreciate you joining us, and so
- 4:15Speaker 4: let's tackle that first question. I'll open up with a
- 4:17Speaker 4: comment and then let Nick is a well comment. So
- 4:20Speaker 4: look at I think the big thing about Terrace is
- 4:23Speaker 4: still very unknown water. It's very murky, and we're trying
- 4:28Speaker 4: to struggle our way through whether it's a brand organization
- 4:32Speaker 4: or whether it's a generic organization. But ultimately we are
- 4:35Speaker 4: going to have to absorb this change that's in front
- 4:39Speaker 4: of us, and that how we absorb that is going
- 4:43Speaker 4: to impact throughout the supply chain or value chain within healthcare. Likely.
- 4:48Speaker 4: I would think Nick would agree that a lot of
- 4:50Speaker 4: it's going to be on the shoulders of the manufacturers
- 4:52Speaker 4: first and foremost until it evolves over time. And I
- 4:56Speaker 4: do agree with the headline. I do think that you know,
- 5:00Speaker 4: branded organizations are going to be hit and we'll endure it.
- 5:03Speaker 4: I think the generic side of the business is probably
- 5:06Speaker 4: going to have a greater threat. As the headline says,
- 5:09Speaker 4: I think it's going to have some downstream effects that
- 5:13Speaker 4: could obviously first and foremost impact financials, but I think
- 5:17Speaker 4: more importantly it could change those financials dynamics and the
- 5:21Speaker 4: cost of doing business because of some of this additional
- 5:24Speaker 4: pressure could delete the things that will actually see a
- 5:26Speaker 4: rationalization of some of the generic companies. There's over four
- 5:29Speaker 4: hundred plus pharmaceutical generic pharmaceutical companies servicing the US market
- 5:35Speaker 4: right now, and in many cases certain products that we
- 5:38Speaker 4: probably have more than we actually need to ensure fair
- 5:41Speaker 4: pricing in the marketplace. I think the other thing that's
- 5:43Speaker 4: going to happen is that it could create an even
- 5:46Speaker 4: greater pressure on drug shortage, and how that impacts us
- 5:51Speaker 4: then means it goes to it makes it more difficult
- 5:53Speaker 4: for companies to continue to produce some products that might
- 5:57Speaker 4: not have a significant margin as results, and we've seen
- 6:01Speaker 4: this historically over the last couple of years, companies stop
- 6:03Speaker 4: producing certain products, creating that shortage, and then it obviously
- 6:08Speaker 4: trickles down to the ability of pharmacists getting ahold of
- 6:11Speaker 4: the product and the patient ultimately having it. So I
- 6:14Speaker 4: think there's a lot to unravel with the tariffs, and
- 6:17Speaker 4: I think we're going to see it evolve and change.
- 6:20Speaker 4: Positions today might be different, but we are going to
- 6:23Speaker 4: have to find a way to endure it, as the
- 6:26Speaker 4: headline said, and find a way to work through the
- 6:29Speaker 4: system so that ultimately everybody's still healthy at the end
- 6:33Speaker 4: of it, meaning pharmaceutical companies can still produce products, wholesalers,
- 6:37Speaker 4: distributors and pharmacists can get the product and ultimately the
- 6:42Speaker 4: available to them in a ready format with high quality products.
- 6:46Speaker 4: But Nick, what do you think about this topic?
- 6:48Speaker 5: Well, I mean, yeah, we're seeing so much speculation these
- 6:51Speaker 5: days as to you know, what's going to happen with tariffs,
- 6:53Speaker 5: how are they going to affect our organization or this organization,
- 6:57Speaker 5: or what's going to happen along the supply chain if
- 6:59Speaker 5: in fact tariffs hit. We don't know, but the headline
- 7:03Speaker 5: is a good one. You know, pharmaceutical big pharma is
- 7:06Speaker 5: likely to endure this. There's a lot more latitude in
- 7:09Speaker 5: pricing of branded pharmaceutical prices. They have the more wherewithal
- 7:15Speaker 5: them do. A lot of generic companies that are working
- 7:18Speaker 5: on razor thin margins on various products across the spectrum.
- 7:22Speaker 5: So yeah, I agree. I think you know, if tariffs
- 7:26Speaker 5: aren't put into place, big pharmaceutical companies will figure out
- 7:30Speaker 5: a way to work within the system to make prices
- 7:34Speaker 5: still reasonable for the patients who ultimately need the product,
- 7:39Speaker 5: but that's going to be more and more challenging for
- 7:41Speaker 5: the generics. Generics will take the brunt of the hit
- 7:45Speaker 5: and will suffer more. And also, if you look at
- 7:50Speaker 5: that kind of statistically, you see that many of the
- 7:53Speaker 5: products that are sold in the United States on the
- 7:54Speaker 5: branded side are either coming from the United States manufacturers
- 8:00Speaker 5: or from international companies that can, in fact, at some
- 8:04Speaker 5: point manufacturer in the United States. That is not true
- 8:06Speaker 5: with the generic manufacturers. They tend to be x US
- 8:11Speaker 5: and will be hit harder. Ostensibly, will be hit harder
- 8:15Speaker 5: with the advent of these tariffs if they come out
- 8:17Speaker 5: the way that most people are speculating right now. So
- 8:20Speaker 5: I guess the expression is Stephen, I'm in violent agreement
- 8:23Speaker 5: with you.
- 8:24Speaker 4: Well, you know, I agree with you as well. Nick.
- 8:27Speaker 4: I think one of the interesting things is, you know,
- 8:29Speaker 4: with anything that happens, I'm always of the belief that
- 8:33Speaker 4: there could be good and bad or challenges and opportunity,
- 8:36Speaker 4: and I think there is a spirit behind this to
- 8:41Speaker 4: ensure that the US market in particular has you know,
- 8:45Speaker 4: affordable medicine and pricing and favored nation pricing is obviously
- 8:50Speaker 4: one of the topics that's spinning out from the whole
- 8:52Speaker 4: tariff situation, and that might open up the door for
- 8:55Speaker 4: a greater conversation about how the system really works and
- 8:58Speaker 4: where the value in the system. And I'll see that,
- 9:01Speaker 4: you know, there's always can be good and bad players,
- 9:04Speaker 4: but I will see that there's an opportunity that is
- 9:07Speaker 4: not really the manufacturers themselves that are are the ones
- 9:10Speaker 4: that are causing a lot of these challenges. And then ultimately,
- 9:14Speaker 4: you know, the goal is to create balance in product
- 9:18Speaker 4: security in terms of more manufacturing back in the US.
- 9:23Speaker 4: API manufacturing is almost exclusively offshore in Asia Pacific, in
- 9:29Speaker 4: China and India. You know, how do we create that
- 9:32Speaker 4: balance universally, not just in the US, but globally so
- 9:37Speaker 4: that we don't find ourselves in these positions of weakness
- 9:40Speaker 4: in terms of either drug supply or being able to
- 9:43Speaker 4: manage control a price. And believe me, as manufacturers, we
- 9:47Speaker 4: certainly look at ways to control price in order to
- 9:50Speaker 4: maintain accessibility to our products, whether they're brand or generic.
- 9:55Speaker 4: But I think now it's time to kind of jump
- 9:57Speaker 4: into the theme of this and this first inaugural episode,
- 10:00Speaker 4: so it's very exciting. Is to is to really take
- 10:03Speaker 4: no pun intended, a generic approach to kind of a
- 10:05Speaker 4: couple of broad topics because we really want to kind
- 10:09Speaker 4: of set the stage of what's to come behind it.
- 10:11Speaker 4: And as we move down through the monthly podcast, we'll
- 10:15Speaker 4: get into topics that I think are very timely, and
- 10:17Speaker 4: we'll get more specific into smaller set of topics. But
- 10:21Speaker 4: we thought the way to kick off is to kind
- 10:23Speaker 4: of look at a couple areas. And the first question is, Nick,
- 10:27Speaker 4: when we look at the state of the pharmaceutical industry
- 10:29Speaker 4: in twenty twenty five, what are the things that come
- 10:32Speaker 4: to mind to you?
- 10:33Speaker 5: I look at the industry pretty broadly, and I have
- 10:35Speaker 5: to say that what I see is very robust. We're
- 10:38Speaker 5: seeing really good growth, We're seeing good development. You look
- 10:42Speaker 5: at the GLP one products. Everybody points to them as well,
- 10:45Speaker 5: these are a great breakthrough and they are. We're making
- 10:48Speaker 5: great breakthroughs in oncology as well. You see that in
- 10:51Speaker 5: addition to this, you see it in rare diseases immunology,
- 10:55Speaker 5: So robust research and development or robust pipe lines for organizations,
- 11:02Speaker 5: we're using AI machine learning to put help products go
- 11:07Speaker 5: through the development process that much quicker. So there are
- 11:12Speaker 5: a lot of moving parts, but they're moving our industry
- 11:15Speaker 5: in the right direction without a doubt. Now that's the positive,
- 11:19Speaker 5: of course, and I think by far the positives outweigh
- 11:23Speaker 5: the negatives. But we see some significant negatives. And depending
- 11:26Speaker 5: on how you capture this or how you intellectualize things
- 11:29Speaker 5: like the tariffs or most favored nation or the whole
- 11:33Speaker 5: idea of the challenges with the supply chain COVID, these
- 11:37Speaker 5: can be seen as negative. But you know, we're where
- 11:41Speaker 5: we have control a lot of the supply chain. We're
- 11:43Speaker 5: working through some of the kinks that that are problematic,
- 11:46Speaker 5: and you could just characterize for right now, we can
- 11:49Speaker 5: characterize the tariff in the most favored nation situation as
- 11:52Speaker 5: an unknown. Yes, we're trying to work around it, we're
- 11:56Speaker 5: trying to speculate, but in large measure, the industry is robust.
- 12:00Speaker 5: The industry is solid, moving in the right direction, and
- 12:04Speaker 5: really significant breakthroughs in medicine happening over the course of
- 12:07Speaker 5: GOSH the next call it six months, the year, three years,
- 12:11Speaker 5: whatever time period you choose. I think we're going to
- 12:14Speaker 5: see some monumental changes to some significant disease states.
- 12:19Speaker 4: Yeah, I think Nick raises some good points. I think
- 12:21Speaker 4: that you know, there is a lot of positive signs
- 12:25Speaker 4: of things will continue to get better. We need to
- 12:27Speaker 4: continue to find ways to allow branded companies to invest
- 12:31Speaker 4: in new chemical entity, especially in rare disease or orphan disease,
- 12:34Speaker 4: as you mentioned. I think that you know, we'll continue
- 12:38Speaker 4: to see changes in the FDA. And historically the FDA
- 12:42Speaker 4: has been criticized for the number of product approvals, but
- 12:48Speaker 4: we're starting to see some processes that might improve it.
- 12:50Speaker 4: But interesting enough, we also still have this constant dynamic
- 12:53Speaker 4: back and forth because if I've just read an article
- 12:56Speaker 4: the other day that I forget the exact number, but
- 13:00Speaker 4: percent of all the andos or the generic drug approvals.
- 13:04Speaker 4: Actually we're not commercialized. So although we are making improvements
- 13:08Speaker 4: and things like or a DA approvals, the question is
- 13:12Speaker 4: how is that enhancing the market in terms of patient access,
- 13:18Speaker 4: costs and so forth. So what we're seeing is that
- 13:20Speaker 4: in certain areas we might have products that are just
- 13:22Speaker 4: not viable to a company to launch even though they
- 13:25Speaker 4: went through the process of getting it approved. I think
- 13:27Speaker 4: there's another thing that and this is what I think
- 13:31Speaker 4: is going to be really fascinating as we continue to
- 13:32Speaker 4: look at these kind of layers and when when we
- 13:35Speaker 4: look at it through the delivery from a manufacturer to patient,
- 13:39Speaker 4: is things like the cost of doing business in the
- 13:43Speaker 4: US has become very very different and more challenging. You know, Historically,
- 13:47Speaker 4: when I first got in this industry many many years ago,
- 13:50Speaker 4: multiple decades, I won't tell how many, but you know,
- 13:54Speaker 4: we could look at the US as kind of as
- 13:56Speaker 4: a market, and now we have to kind of look
- 13:58Speaker 4: at it as fifty different markets because each state has
- 14:01Speaker 4: many different dynamic requirements and not all of them are
- 14:05Speaker 4: the same state licensing our ability just to sell our
- 14:08Speaker 4: product in the state. Now I think it's thirty six
- 14:11Speaker 4: states now roughly now have state licensing requirements, so you know,
- 14:17Speaker 4: we have to fully understand. I think that's what the
- 14:20Speaker 4: power of this podcast is going to be about, is
- 14:21Speaker 4: to fully take topics and see how it impacts all
- 14:25Speaker 4: the way through the value chain in healthcare, because it's
- 14:30Speaker 4: there's a lot of hidden things that put a lot
- 14:31Speaker 4: of pressure on manufacturing. If all of a sudden, we
- 14:34Speaker 4: have all these additional costs. We now have states that
- 14:37Speaker 4: require companies that they want to sell in their states,
- 14:40Speaker 4: the support SHARPS programs for needle disposal. I mean, again,
- 14:44Speaker 4: it might not seem a lot, but when you start
- 14:46Speaker 4: adding it up and adding it up and adding it up,
- 14:48Speaker 4: and then Nix mentioned earlier, you know, some of the
- 14:50Speaker 4: products that we sell don't have rich margins. You know
- 14:53Speaker 4: they don't, so all of a sudden it becomes more
- 14:56Speaker 4: challenging when we're looking at continue investment in development. But
- 15:00Speaker 4: so we have a lot of things like that. I
- 15:02Speaker 4: think one of the interesting things Nick and I were
- 15:04Speaker 4: talking before we came on the podcast today was how
- 15:08Speaker 4: the current system works is how manufacturers have to now
- 15:11Speaker 4: work really hard to find workarounds. One of those workarounds
- 15:15Speaker 4: is how companies are getting the patients and trying to
- 15:18Speaker 4: come up with more direct pathways to the patient. And Nick,
- 15:22Speaker 4: maybe you want to comment on that.
- 15:23Speaker 5: Yeah, it is pretty fascinating and it happened in a
- 15:27Speaker 5: very short period of time. When you talk about the
- 15:31Speaker 5: digital approach to marketing that has happened, you know that
- 15:34Speaker 5: somewhat evolved, but now we go from the digital approach
- 15:37Speaker 5: to market and marketing and touching patients to really having
- 15:41Speaker 5: a direct manufacturers having a direct interaction or interface with customers,
- 15:45Speaker 5: which as an industry, we had thought about this for
- 15:48Speaker 5: quite some time, but it never came to the foe
- 15:50Speaker 5: like it has very recently with companies like Eli, Lilly
- 15:53Speaker 5: and Ffiser having programs where a patient can directly interface
- 15:57Speaker 5: with the patient with a manufact get the product and
- 16:02Speaker 5: and and have a relationship a you know, a product
- 16:06Speaker 5: distributor relationship with the manufacturer. Those types of things have
- 16:10Speaker 5: evolved very rapidly. And uh and you know, once the
- 16:14Speaker 5: cat is out of the bag or the horse leaves
- 16:16Speaker 5: the barn, or whatever expression you want to use, these
- 16:19Speaker 5: things are going to continue to evolve and continue to grow.
- 16:21Speaker 5: So again, it's something that you know, this podcast is
- 16:25Speaker 5: oriented towards pharmacist. It's something that we're you know, pharmacists
- 16:29Speaker 5: and manufacturers alike are going to have to figure out, well,
- 16:32Speaker 5: what we still have a symbiotic relationship in so many ways,
- 16:35Speaker 5: you know, how do we continue that relationship in the
- 16:38Speaker 5: face of certain organizations going out and dealing directly with
- 16:42Speaker 5: patients in certain cases with certain certain products. It might
- 16:46Speaker 5: make good sense to to go down that road. In others,
- 16:49Speaker 5: it might the traditional relationship that has evolved over over many,
- 16:54Speaker 5: many decades might continue to make the most sense. So
- 16:58Speaker 5: on the one hand, it is happening very rapidly, on
- 17:00Speaker 5: the other we really have to kind of observe it
- 17:02Speaker 5: and see what is going to make the most sense
- 17:04Speaker 5: for all players involved, be it manufacturers, be it patients,
- 17:08Speaker 5: be it pharmacies or payers, middlemen in the middle.
- 17:12Speaker 4: Yeah, you know, I think what's really interesting about this
- 17:14Speaker 4: is that I think the sub the theme of it
- 17:18Speaker 4: is we have to find ways to work or in
- 17:22Speaker 4: a system that is not perfect, a system that makes
- 17:26Speaker 4: it very challenging for all of us, especially on the
- 17:29Speaker 4: manufacturer side and the pharmacy side, and as we as
- 17:32Speaker 4: manufacturers have to try to find ways to you know,
- 17:35Speaker 4: at the end of the day, we have to be
- 17:38Speaker 4: profitable companies. If we're not profitable, we can't continue to produce.
- 17:41Speaker 4: So if we're not profitable, we can't continue to develop
- 17:43Speaker 4: and invest in new alternatives or new chemical entities or
- 17:47Speaker 4: whatever it might be our particular focus of our business.
- 17:50Speaker 4: So we have to start finding these ways to go
- 17:52Speaker 4: around and direct. The patient is one of them, but
- 17:54Speaker 4: we also don't want collateral damage. And one of the
- 17:58Speaker 4: pharmacists or the pharmacy channel is one it could be
- 18:00Speaker 4: at most at risk. And when we try to find
- 18:02Speaker 4: these passages, are these new pathways to getting product to
- 18:05Speaker 4: patient but also staying profitable and staying in a position
- 18:08Speaker 4: of ability to grow, and we can't have that happen.
- 18:12Speaker 4: So I think what I'm saying is is that ultimately,
- 18:14Speaker 4: if we don't work together, if we don't work better
- 18:16Speaker 4: closer and understand these issues how they really affect us
- 18:19Speaker 4: all the way through the pathway, we're not going to
- 18:21Speaker 4: find as solutions, and I think that's what we're really after.
- 18:24Speaker 4: But you know, I want to go back to the
- 18:26Speaker 4: tariffs so because you know, one of the things that
- 18:28Speaker 4: I think is going to be important about tariffs is
- 18:30Speaker 4: not only how we manage working with customs and the
- 18:34Speaker 4: operational elements of it or the financial side. On the
- 18:37Speaker 4: cost standpoint, it is going to be it's going to
- 18:40Speaker 4: open up a greater kind of perspective, whether it's correct
- 18:45Speaker 4: or not, in the public domain about you know, the
- 18:49Speaker 4: cost of drugs is, which has always been there. So
- 18:51Speaker 4: then you're talking about things like public trust. So Nick,
- 18:55Speaker 4: do you think the tariff's situation is going to create
- 18:58Speaker 4: more demand on us to continue to work even harder
- 19:01Speaker 4: on trying to manage that existing, if not increasing, dynamic
- 19:06Speaker 4: around public trust with pharmacyal manufacturers.
- 19:08Speaker 5: That it's a tough question.
- 19:10Speaker 4: Well, that's why I'm the host and you're the guest.
- 19:12Speaker 5: I think a lot of this depends on how ultimately
- 19:17Speaker 5: the tariffs manifest themselves.
- 19:18Speaker 3: Right.
- 19:19Speaker 5: If, in fact what happens is that manufacturers are left
- 19:23Speaker 5: with no choice other than to raise the price of
- 19:25Speaker 5: the products, that is going to be seen as initially,
- 19:30Speaker 5: not overall, but initially that will be seen as, to
- 19:34Speaker 5: use your vernacular, breaking the trust with the American public. However,
- 19:39Speaker 5: admittedly we as an industry have not done a very
- 19:41Speaker 5: good job of this. But what we will need to
- 19:44Speaker 5: be doing is to explain to the American public and
- 19:47Speaker 5: chapter and verse, in a very simply simple way, exactly
- 19:52Speaker 5: how the system works. If you will, I'll use the
- 19:54Speaker 5: air quotes for those of you who can't see how
- 19:56Speaker 5: the system works and where the the value is being
- 20:02Speaker 5: in one case added and in one case extracted. So
- 20:05Speaker 5: the value add is the actual asset helping the patient
- 20:09Speaker 5: get better because they have a certain illness, where the
- 20:13Speaker 5: value is being extracted, is getting the product from the
- 20:16Speaker 5: manufacturer to that patient, be it the managed care organization
- 20:21Speaker 5: and the PBMs, with the value extraction there and the
- 20:27Speaker 5: forced increase in the prices potentially whatever that case may be.
- 20:31Speaker 5: And I think we're all in the industry pretty well
- 20:34Speaker 5: aware of where the pitfalls are and in terms of
- 20:39Speaker 5: in terms of value add and value extraction, but we're
- 20:42Speaker 5: going to have to be able to communicate that in
- 20:44Speaker 5: a much much better way to the American public because
- 20:46Speaker 5: I think if you were to ask any individual who's
- 20:49Speaker 5: not in our industry, very broadly, in our industry, be
- 20:54Speaker 5: it insurance, be it a PBM, be it a manufacture,
- 20:57Speaker 5: be it a pharmacy, if you ask any individual, they're
- 21:00Speaker 5: not going to be able to quote fifty percent of
- 21:03Speaker 5: where the value is lost in the whole equation with
- 21:06Speaker 5: pharmaceutical products. But we need to We just need to
- 21:09Speaker 5: be that much better there because we are providing a
- 21:13Speaker 5: sub substantial value to the American public and not to
- 21:16Speaker 5: mention helping individuals really get better, get over their illnesses,
- 21:21Speaker 5: help with long term illnesses, et cetera, et cetera. So
- 21:25Speaker 5: that was a long winded answer to your question, Steve,
- 21:27Speaker 5: and I think the tariffs will point out the fact that, yes,
- 21:32Speaker 5: the prices had to increase to pay for the tariffs ultimately,
- 21:38Speaker 5: but the tariffs were just like many other things in
- 21:41Speaker 5: the ecosystem, that the tariffs are not the only consideration
- 21:46Speaker 5: that a pharmaceutical company makes in pricing the products. There
- 21:49Speaker 5: are so many different areas where to the example you
- 21:54Speaker 5: were using before money is extracted along the value chain.
- 21:59Speaker 4: I like what you said. I think for me what's
- 22:01Speaker 4: interesting about the tariffs is that there's it's like an onion,
- 22:04Speaker 4: There's going to be a lot more layers. This is
- 22:06Speaker 4: not just about bringing manufacturing back to the US or
- 22:11Speaker 4: favor nation or right pricing or whatever the terminology people
- 22:14Speaker 4: want to use. But I do think what's important is
- 22:18Speaker 4: that we have to be sensitive about this because there
- 22:20Speaker 4: has been a generic narrative about pharmaceutical industries and how
- 22:25Speaker 4: we price, and we're price gouging. And I do think
- 22:29Speaker 4: we can look at the terrafts as a bad thing,
- 22:30Speaker 4: or we can look at the tarrafs for what they are.
- 22:32Speaker 4: In any situation in life, I think a business, personal, whatever,
- 22:36Speaker 4: you know, everything has a good protocon or good and bad.
- 22:38Speaker 4: And I think the other good thing that could come
- 22:41Speaker 4: out of this, to your point, is we won't have
- 22:44Speaker 4: the full burd of articulating the story that how we
- 22:49Speaker 4: price products, because I think the average American or average
- 22:52Speaker 4: patient gets certain sound bites and they formulated a position.
- 22:56Speaker 4: It's actually been developed over probably the last three decades.
- 22:59Speaker 4: And I think the result of that this is going
- 23:02Speaker 4: to open up, I think, hopefully in a broader scale
- 23:05Speaker 4: a standpoint, how the system really operates, and they'll see
- 23:10Speaker 4: some of the things that are good and some of
- 23:12Speaker 4: the things that are not so good, or the extraction
- 23:15Speaker 4: in and out from a value standpoint. So I think
- 23:18Speaker 4: at the end of the day, we need to embrace
- 23:20Speaker 4: this in a positive way, and we'll have to find
- 23:24Speaker 4: a way that ensures again that we can create that
- 23:27Speaker 4: value all the way through. At the end of the day,
- 23:28Speaker 4: if we take an independent pharmacist in today's world, an
- 23:32Speaker 4: independent pharmacists can actually lose money dispensing certain products, and
- 23:36Speaker 4: they can make money dispensing certain products. But at the
- 23:39Speaker 4: end of the day, if that independent pharmacist is not profitable,
- 23:43Speaker 4: then by virtue of that scenario, they can't stand business.
- 23:47Speaker 4: And an independent pharmacist, like any pharmacist, is important, but
- 23:51Speaker 4: if they're servicing a rural community where there is not
- 23:54Speaker 4: another pharmacy, or they can't service their patients effectively, or
- 23:58Speaker 4: they have to close the door. And we know that
- 24:01Speaker 4: if there's any channel that's having a lot of challenges
- 24:03Speaker 4: and change right now, it is the is the pharmacy channel.
- 24:07Speaker 4: So we have to make sure that we work together
- 24:09Speaker 4: and understand clearly what's going on so that maybe some
- 24:12Speaker 4: improvements in the process will then allow that benefit to
- 24:16Speaker 4: translate again all the way down to the patient exactly. Yeah. So,
- 24:21Speaker 4: you know, if we think about what's unique about having
- 24:24Speaker 4: Nick on the podcast first is that we are two
- 24:28Speaker 4: companies under the umbrella, one being brand and one being generic.
- 24:32Speaker 4: So one of the always interesting questions that I get,
- 24:35Speaker 4: or I'm sure you get many times, Nick, is you
- 24:37Speaker 4: know what perspectives are happening between generic versus brand from
- 24:42Speaker 4: an innovation standpoint or anything else. So any thoughts in
- 24:45Speaker 4: terms of the whole brand generic dynamic as you see
- 24:48Speaker 4: it in the US?
- 24:48Speaker 5: Yeah, I mean, because I have the benefit of being
- 24:52Speaker 5: able to see both at you know, our relatively close range.
- 24:57Speaker 5: I'll kind of repeat a couple of the things that
- 25:00Speaker 5: I had mentioned at the outset about you know, the
- 25:02Speaker 5: form of industry on the brand side is very robust,
- 25:05Speaker 5: some really significant developments in in oncology, in immunology, rare disease,
- 25:10Speaker 5: et cetera, et cetera. So and even anti infectives, which
- 25:14Speaker 5: you know, many people in the industry thought that anti
- 25:17Speaker 5: effective work was really going by the wayside because of
- 25:19Speaker 5: the problems associated with generating revenue, the and the and
- 25:22Speaker 5: the anti effective space, et cetera, et cetera. But we're
- 25:25Speaker 5: seeing even seeing developments there. So there is clear i
- 25:31Speaker 5: would say, not exponential, but at least algorithmic growth in
- 25:35Speaker 5: what's going on in research and development in the on
- 25:38Speaker 5: the branded side of things, and it's across the industry
- 25:41Speaker 5: in many, many different therapeutic areas. The generics are not
- 25:46Speaker 5: without their interesting asset growth as well. And innovation.
- 25:50Speaker 4: I mean, the.
- 25:51Speaker 5: Biosimilars in and of themselves are you know, you could
- 25:54Speaker 5: consider them innovation. They're they're really going to help out
- 25:57Speaker 5: in terms of regulating the the overall costs for the
- 26:03Speaker 5: expensive medications throughout the country. That's going to be very beneficial.
- 26:09Speaker 5: And then you see, you know, some of the more
- 26:11Speaker 5: difficult delivery systems, the injectables at all different levels, really
- 26:17Speaker 5: getting into some areas that are you know, very interesting
- 26:21Speaker 5: and probably not well thought of or not well thought
- 26:23Speaker 5: out up until now. And then it's the generic industry
- 26:26Speaker 5: that it's really pulled them forward in terms of getting
- 26:29Speaker 5: them to a point where you know, it can ratchet
- 26:31Speaker 5: down the costs a little bit and also provide the
- 26:34Speaker 5: same product to the patient at a reduced costs. So,
- 26:38Speaker 5: you know, I see innovation in a couple of different
- 26:41Speaker 5: ways that obviously different on the branded side with the
- 26:45Speaker 5: focus on research and development.
- 26:47Speaker 4: You know, innovation for me, at least the sense for
- 26:49Speaker 4: me the last few years, last five to ten years
- 26:52Speaker 4: has kind of dipped a little bit because of the
- 26:54Speaker 4: dynamics in the marketplace, whether it be regulatory, competitive set,
- 26:58Speaker 4: relative investment margin, where products are being developed. You know,
- 27:01Speaker 4: we've seen a lot of our products being developed outside
- 27:04Speaker 4: the traditional manufacturer in the CDMOS, and I think we're
- 27:07Speaker 4: going to see some evolution of that back. I think
- 27:10Speaker 4: companies that have kind of divested that responsibility are seeing
- 27:13Speaker 4: the need to pull that back in to control of
- 27:16Speaker 4: that innovation or prioritize that innovation. And you're absolutely right
- 27:19Speaker 4: on the generic side. You know, biosimilars is clearly an innovation.
- 27:23Speaker 4: I think, you know, the generic industry has changed dramatically.
- 27:27Speaker 4: You know, we used when I used to work with
- 27:29Speaker 4: my prior company in the generic life, we used to
- 27:31Speaker 4: define generics as small, medium, large. You know, we have
- 27:34Speaker 4: really large generic companies, we have medium companies, we have
- 27:36Speaker 4: small companies, and that kind of dictated where their portfolios went.
- 27:40Speaker 4: But I think now when we really look at the
- 27:42Speaker 4: generic industry from innovation is that we don't describe ourselves anymore.
- 27:47Speaker 4: Now it's either true commodity companies that are really playing
- 27:50Speaker 4: in those high volume, low cost commodity products, and then
- 27:54Speaker 4: everybody else is kind of evolving into more high complex companies,
- 27:58Speaker 4: or maybe a hybrid that's really been seen in a
- 28:01Speaker 4: lot of the larger generic companies where they're not really
- 28:04Speaker 4: wanting to position themselves as a true generic organization, but
- 28:07Speaker 4: as a hybrid brand generic. And I think you know
- 28:10Speaker 4: that's where that continue innovation is. So we've kind of
- 28:13Speaker 4: shifted from this kind of traditional pathway of the most
- 28:16Speaker 4: marbles one the game to having the right marbles. And
- 28:20Speaker 4: I've used that line quite a bit in the past
- 28:22Speaker 4: year at different conferences and so forth. And I think
- 28:25Speaker 4: because of that, it's it's forcing us on the generic
- 28:29Speaker 4: side to be more innovative, and not just innovative and
- 28:32Speaker 4: manufacturing or the type of products, but also in terms
- 28:35Speaker 4: of how we engage. I mean, may most people don't
- 28:39Speaker 4: know is that ninety percent plus of all prescriptions are
- 28:42Speaker 4: filled generically. And then there's that because of that, because
- 28:46Speaker 4: of the innovation starting to creep up on the generic side,
- 28:49Speaker 4: because that's where quite frankly and very honest, that's where
- 28:52Speaker 4: a lot of the profitability comes, or the margin comes.
- 28:55Speaker 4: That brings us a little bit closer to the brand
- 28:57Speaker 4: side to some extent. So you're starting to see that
- 28:59Speaker 4: integrins of not only the type of products, but also
- 29:03Speaker 4: on how we engage the markets. So I think it's
- 29:05Speaker 4: going to continue to create a very unique dynamic. But
- 29:08Speaker 4: the most important thing we have to do is we've
- 29:10Speaker 4: got to create a dynamic that ensures that innovation, to
- 29:12Speaker 4: your point, continues to be fostered in the organization to
- 29:15Speaker 4: create more opportunity for patients. And then we continue to
- 29:19Speaker 4: have that balance between branded generics in order to ensure
- 29:23Speaker 4: access is also there and that we can see that
- 29:26Speaker 4: historically and now we're going to start seeing biosomas follow
- 29:29Speaker 4: the path of more traditional generics. But you know, funny enough,
- 29:33Speaker 4: you know, you know, not too long ago, injectables were
- 29:35Speaker 4: considered complex products, and now they're a commodity because we're
- 29:38Speaker 4: now having to find newer innovation, whether it's dual chamber
- 29:42Speaker 4: bags or you know, we've gone from shyringe and bile
- 29:45Speaker 4: now that everything has to be pre filled and things
- 29:47Speaker 4: like that. So it's going to be very interesting how
- 29:49Speaker 4: that continues to grow innovation. You know, let's just change
- 29:52Speaker 4: gears a little bit. We talked a little bit about
- 29:54Speaker 4: some of the you know, the current trends and things
- 29:56Speaker 4: from an industry overview, but you know, from a kind
- 29:59Speaker 4: of a CEO perspective, if you think about strategy and
- 30:01Speaker 4: growth and ultimately patient focus, you know, how do you
- 30:06Speaker 4: see IPS USA having to navigate today's industry headwinds along
- 30:11Speaker 4: those lines? How do you continue to prioritize growth and
- 30:14Speaker 4: innovation and still meet patient needs and all those type
- 30:17Speaker 4: of topics that we discuss every day.
- 30:19Speaker 5: Yeah, again, you know, it's a it's a tall order
- 30:22Speaker 5: to answer that question because it's there's so many moving
- 30:26Speaker 5: parts to what's going on. In our universe. And now
- 30:29Speaker 5: with everything that we've talked about, right, we've got most
- 30:32Speaker 5: favored nation kind of hanging out there in the balance.
- 30:34Speaker 5: We've got the tariff issue going on. We are an
- 30:37Speaker 5: international manufacturer, so we have we have that issue of
- 30:41Speaker 5: you know, the tariffs loom and we manufacture and countries
- 30:45Speaker 5: that will be hit hard if those tariffs come to
- 30:48Speaker 5: the fore in the not too distant future. So the
- 30:52Speaker 5: navigation navigating the headwinds is you know, right right now,
- 30:56Speaker 5: it's it's like putting our heads down and making things,
- 31:00Speaker 5: making things happen in the here and now, because that's
- 31:03Speaker 5: all we have. But we've got to be continually planning
- 31:06Speaker 5: for the future in terms of, Okay, we know this
- 31:09Speaker 5: could happen, do we do we contemplate any any movement
- 31:13Speaker 5: of manufacturing facilities. Well, that's that's not a tomorrow thing,
- 31:16Speaker 5: as you know, Steven, that that's that's a that's a
- 31:19Speaker 5: two year, five year commitment, and you know what will happen,
- 31:22Speaker 5: what will transpire in that amount of time. We give
- 31:25Speaker 5: rational thoughts of these things, but the decision points are
- 31:27Speaker 5: really going on some of them are just going to
- 31:29Speaker 5: have to wait until we actually see how how the
- 31:32Speaker 5: laws play out from the federal government on down. You
- 31:36Speaker 5: mentioned something that was interesting before that we never really
- 31:39Speaker 5: we never talked about too much after that. But you know,
- 31:41Speaker 5: we most of us look at the United States as
- 31:43Speaker 5: you know, you know, fifty states, which obviously it is,
- 31:47Speaker 5: but those individual states can can really the dynamics within
- 31:51Speaker 5: those fifty states are vastly different for a company like ours,
- 31:54Speaker 5: and I'm sure like most pharmaceutical companies, so we have
- 31:57Speaker 5: to in many cases we have to engage with individual
- 32:00Speaker 5: states and that is a challenge as well. So again,
- 32:05Speaker 5: you know, this this universal, this universal swirl as I
- 32:09Speaker 5: like to call it, this there's so many things going
- 32:11Speaker 5: around that, you know, you have to kind of pick
- 32:14Speaker 5: and choose your battles, but you also have to put
- 32:16Speaker 5: your head down and work with what you have right now.
- 32:18Speaker 4: Yeah, I think, you know, today the headwinds are still strong.
- 32:22Speaker 4: I think, as you pointed out earlier, there's certainly opportunities,
- 32:25Speaker 4: but the you know, the headwinds are are are still fierce,
- 32:30Speaker 4: you know, because we do have constant downward pressure on
- 32:34Speaker 4: pricing from for very good reasons, maybe not some good reasons.
- 32:39Speaker 4: We have costs are going up, So how do we
- 32:42Speaker 4: continue to do uh, navigate through this in a way
- 32:45Speaker 4: that we can achieve. You know, the business metrics, I
- 32:50Speaker 4: mean the business metrics, whether it's in this pharmaceutical industry
- 32:53Speaker 4: or the IT industry or the automotive industry is ultimately
- 32:57Speaker 4: it's you know, in a capitalist society, we have to
- 32:59Speaker 4: we have to make profit, either to satisfy our shareholders
- 33:03Speaker 4: or owners or that's just simply how do we continue
- 33:06Speaker 4: to be able to progress and go forward. In the
- 33:08Speaker 4: pharmaceutical industry, you know, that's very evident. Uh, you know,
- 33:12Speaker 4: technology industry is certainly you know, if you're not advancing
- 33:15Speaker 4: your ultimately life catches up to you. And I think
- 33:19Speaker 4: that's where that that fine balance comes in. So we
- 33:21Speaker 4: need to find a way to do it. But you know,
- 33:24Speaker 4: we have to prioritize growth and growth. I think the
- 33:29Speaker 4: definition of growth for me might be different. You know,
- 33:32Speaker 4: our company is going to have to think about it
- 33:34Speaker 4: differently in terms of growth because it can't just be dollars.
- 33:37Speaker 4: Growth has to be in terms of how you approach
- 33:39Speaker 4: a portfolio of development. Growth is in terms of how
- 33:42Speaker 4: you reach different types of patients through that development that
- 33:45Speaker 4: you do. So I think those are things that we
- 33:48Speaker 4: have to find a way. But the traditional way we
- 33:50Speaker 4: have done things has been a response to the way
- 33:54Speaker 4: traditionally the industry has worked. And now you've got things
- 33:56Speaker 4: being like the tears that are going to force beyond
- 33:59Speaker 4: the tear if itself is going to correct create change,
- 34:01Speaker 4: and we have to be prepared, uh to to navigate
- 34:04Speaker 4: through that so we're not finding those end around opportunities
- 34:08Speaker 4: that might not be beneficial to everybody in the system
- 34:11Speaker 4: and find some solutions that will be consistent through the
- 34:15Speaker 4: whole system down to the patient. One of the questions
- 34:17Speaker 4: is what's the role of leadership right now in guiding
- 34:20Speaker 4: this change? I mean, as as a CEO, what do
- 34:22Speaker 4: you think are some of the most important things that
- 34:24Speaker 4: you have to be or you are thinking about on
- 34:26Speaker 4: a daily basis in terms of decisions that are being
- 34:30Speaker 4: made in order to translate.
- 34:31Speaker 5: That value all the way down and look at leadership
- 34:34Speaker 5: is you know, obviously empowering individuals to do the best
- 34:39Speaker 5: that they can in this complex environment. We also have
- 34:43Speaker 5: to provide some vision. We have to we have to
- 34:45Speaker 5: provide kind of the end game, the goal for individuals
- 34:49Speaker 5: to work towards. And I think you know, once you
- 34:52Speaker 5: have provided that vision. Hey, this is what we're going
- 34:55Speaker 5: to be doing over the course of the next six
- 34:57Speaker 5: months and the next the next year, and this is
- 35:00Speaker 5: how we work to it. Your job, then is to
- 35:04Speaker 5: keep the superfluous stuff aside, push aside the distractions for individuals.
- 35:09Speaker 5: And believe me, the tariff issue the most favored nation
- 35:11Speaker 5: is a major distraction because people will love to talk
- 35:14Speaker 5: about it as much as much as they can, but
- 35:17Speaker 5: really it's just a swirl because they don't have any
- 35:20Speaker 5: of the facts. So again, provide that vision, clear out
- 35:24Speaker 5: the clutter, be it intellectual clutter or actual physical clutter,
- 35:28Speaker 5: to let them get do their jobs and get things done.
- 35:31Speaker 5: I think if I, as a leader can make those
- 35:34Speaker 5: few things happen, then we can continue to move our
- 35:38Speaker 5: business forward. We have smart people in the right places,
- 35:40Speaker 5: as most companies do. People know how to do their job.
- 35:44Speaker 5: They just need to kind of be released from this
- 35:47Speaker 5: constant worry about the swirl in the background and say, hey,
- 35:51Speaker 5: this is what I have in front of me, this
- 35:52Speaker 5: is what I can do, and I'm going to go
- 35:53Speaker 5: do it.
- 35:54Speaker 4: Yeah, I agree with you, Nick, I think that any
- 35:57Speaker 4: good leader is going to have to be able to
- 35:59Speaker 4: provide clear vision and I think the outcome of clear vision.
- 36:03Speaker 4: One of the most important things is clarity. And when
- 36:06Speaker 4: we're talking about all these headwinds and all these different
- 36:09Speaker 4: things that are impacting and as a manufacturer, again, I
- 36:11Speaker 4: don't think people always underderstand. We have to understand this
- 36:15Speaker 4: all the way through. Right, we have to navigate the
- 36:17Speaker 4: regulatory side, and when we're trying to get products approved
- 36:19Speaker 4: or maintaining products, we have to navigate the supply side.
- 36:22Speaker 4: We've got to navigate the delivery of products at the
- 36:25Speaker 4: pharmacy and the patient and physicians. I don't know if
- 36:28Speaker 4: people really maybe appreciate it's not just us manufacturing products
- 36:32Speaker 4: and putting it on the shelf. There are many many
- 36:34Speaker 4: layers to this. And then when you add things like
- 36:36Speaker 4: we talked about earlier, like managing operationally in a market
- 36:41Speaker 4: that you in essence don't have one market but fifty.
- 36:44Speaker 4: That takes time, that takes effort, that takes resource, and
- 36:48Speaker 4: I think that's the problem. So you know, when we
- 36:50Speaker 4: have all this noise going on, you know, vision provides clarity,
- 36:54Speaker 4: and I think on top of that, if you can
- 36:56Speaker 4: for me as a leader, I think that communication is
- 36:59Speaker 4: all something I talked about. I think it's fundamental along
- 37:03Speaker 4: with culture. If you can't do that, and granted, communications
- 37:07Speaker 4: should be part of culture, part of a good culture,
- 37:10Speaker 4: but you've got to communicate well. And I think when
- 37:12Speaker 4: we face all these issues and changes on uncertainty, we've
- 37:16Speaker 4: got to find a better way as an industry to
- 37:20Speaker 4: communicate clearly and consistently so that the right message ultimately
- 37:26Speaker 4: prevails and gets to the top. And then I think
- 37:28Speaker 4: when that happens, more people will understand, more people will
- 37:30Speaker 4: be aligned, and as a result of that, we'll find
- 37:33Speaker 4: more solutions to it.
- 37:34Speaker 5: And if at the very least they might understand the
- 37:37Speaker 5: reason for the expense of some pharmaceutical products, if they understood,
- 37:40Speaker 5: if people understood, you know, getting the full development process,
- 37:44Speaker 5: what it costs to do pre clinical work, to phase one,
- 37:47Speaker 5: to phase two, to phase three, to get to get
- 37:50Speaker 5: a product through the FDA, and then to do phase
- 37:52Speaker 5: four work when when that's necessary or required by the FDA.
- 37:55Speaker 5: And then oh, by the way, we have to get
- 37:57Speaker 5: the product from point A to point B, so there's
- 37:59Speaker 5: all the supply chain along the way. And unlike other industries,
- 38:04Speaker 5: many other industries, we can't just sell a product and
- 38:06Speaker 5: wash our hands of it. We have pharmacovigilance issues to
- 38:10Speaker 5: worry about, We have yearly reports to worry about with
- 38:12Speaker 5: the FDA. So there are a lot of moving parts,
- 38:17Speaker 5: and certainly a lot of those moving parts the general
- 38:21Speaker 5: public doesn't necessarily They might think about in the background,
- 38:24Speaker 5: but they don't necessarily know fully what goes into making
- 38:30Speaker 5: things happen to get a product from inception concept all
- 38:34Speaker 5: the way to a patient and to the point I
- 38:37Speaker 5: think we're both making we need we as an industry
- 38:39Speaker 5: can tell that story much better than we're doing today.
- 38:41Speaker 4: Yeah, and you know, and again maybe that's the silver
- 38:44Speaker 4: lying in the TEARFF situation is going to expose some
- 38:47Speaker 4: of the things in a way that we can make
- 38:50Speaker 4: some adjustments, make the system work better and still make
- 38:54Speaker 4: everybody that's involved in the system successful. But at the
- 38:58Speaker 4: end of the day, we still are six US starts
- 39:00Speaker 4: and finishes with us being able to deliver value to
- 39:04Speaker 4: the patients. There's a product that IPSA has that there
- 39:07Speaker 4: is a generic dynamic in it, but there's seventeen suppliers
- 39:11Speaker 4: of the same product. We sometimes have to refresh what
- 39:15Speaker 4: we're trying to accomplish, and they if you go back
- 39:17Speaker 4: to generics generics were put in place to create a
- 39:21Speaker 4: high quality, affordable products that were more accessible to the
- 39:24Speaker 4: total population. And that's the really good thing. Now, maybe
- 39:29Speaker 4: you say we didn't need generics, that we changed other
- 39:31Speaker 4: things like patent laws and other things that create different dynamics,
- 39:34Speaker 4: but the fact is that was a premise. But sometimes
- 39:37Speaker 4: you can you can actually over overshoot the target a
- 39:40Speaker 4: little bit, because now we've created a dynamic where it's
- 39:45Speaker 4: it's not fair pricing or right pricing, it's best pricing.
- 39:49Speaker 4: It's it's creating more variability to the patients that get
- 39:53Speaker 4: those products because of the diversity of manufacturing. So maybe
- 39:56Speaker 4: in some of this will increase the ability to protect
- 40:00Speaker 4: those essential products, create more opportunity within the market us
- 40:05Speaker 4: stabilized pricing a little bit, and maybe right size not
- 40:08Speaker 4: that I you know, well, maybe it sounds competitive when
- 40:11Speaker 4: I say right size out some of the you know,
- 40:14Speaker 4: the natural competitors or number of players, But I think
- 40:16Speaker 4: that that is contributing to some of the challenges that
- 40:20Speaker 4: we have and if we can fix that, then that
- 40:21Speaker 4: that value can also translate all the way down to
- 40:24Speaker 4: the pharmacy and ultimately the patient. So but the time
- 40:26Speaker 4: you have left that really was going to maybe talk
- 40:29Speaker 4: one more topic, and that is, you know, portfolio expansion.
- 40:33Speaker 4: You know, so we talked about innovation, We've talked about
- 40:35Speaker 4: the pressures on the existing portfolios, but at the end
- 40:38Speaker 4: of the day, pharmaceutical industry, whether it's brand or generic,
- 40:42Speaker 4: really kind of live or die by their pipeline and
- 40:46Speaker 4: their portfolio expansion or the creation of that. So how
- 40:50Speaker 4: do you think, you know, from your perspective, good companies
- 40:54Speaker 4: are going to have to look at how they approach
- 40:57Speaker 4: that either internally externally to deliver on an ever evolving
- 41:02Speaker 4: and growing portfolio.
- 41:03Speaker 5: Yeah, that's that's interesting and a lot has been written
- 41:06Speaker 5: of it lately because clearly most companies from you know,
- 41:11Speaker 5: from the largest research and development companies on down to
- 41:15Speaker 5: you know, small biotechs, they have their own portfolio stable
- 41:21Speaker 5: if you will, of products that are either in development
- 41:24Speaker 5: or pre or maybe in concept right now but moving forward.
- 41:29Speaker 5: But why you're reading a lot about it now is
- 41:31Speaker 5: because with the advent of machine learning and AI, the
- 41:36Speaker 5: processes are just increasing. The velocity of which these the
- 41:42Speaker 5: new potential new chemical entities are coming on board is
- 41:47Speaker 5: is just phenomenal. So now it's a good kind of
- 41:50Speaker 5: problem to have is that you know, there these ourselves included,
- 41:55Speaker 5: we're choosing among lots of different pipeline products. So now
- 41:59Speaker 5: we're value wating. Okay, well, what's the most needed in
- 42:02Speaker 5: the marketplace? Where do we see the most patients suffering
- 42:05Speaker 5: or patients that don't have there are no potential treatments
- 42:09Speaker 5: for them right now, or a small population allah the
- 42:12Speaker 5: orphan or rare disease situation. You know, how are we
- 42:16Speaker 5: going to approach these markets because now we have you know,
- 42:19Speaker 5: potentially more candidates, more drug candidates. Yes, but also what
- 42:25Speaker 5: hasn't changed in this whole equation is the pathway, the
- 42:28Speaker 5: regulatory pathway to get them approved. So that's always going
- 42:32Speaker 5: to be I won't call it a stumbling block, but
- 42:35Speaker 5: it is a It is an element of time that
- 42:38Speaker 5: has to be considered so to to get you a
- 42:41Speaker 5: better answer to your question, how do I see it evolving?
- 42:44Speaker 4: Well?
- 42:44Speaker 5: I see us still you know, picking from our stable
- 42:47Speaker 5: of known products that are already have been kind of identified.
- 42:52Speaker 5: But I see AI in a lot of ways helping
- 42:54Speaker 5: us through that process and also helping to develop new
- 42:58Speaker 5: They're not developing or not finding new chemical entities, but
- 43:01Speaker 5: they're being fed the information that will ultimately churn out
- 43:03Speaker 5: potential new chemical entities that will be beneficial to many,
- 43:07Speaker 5: many different organizations.
- 43:09Speaker 4: I agree. I think you know, you take a therapeutic
- 43:12Speaker 4: area like asthma, we haven't seen a lot of innovation
- 43:15Speaker 4: in terms of the new therapeutic options we've seen as
- 43:20Speaker 4: the lack of that we've seen. Actually, what they've done is,
- 43:22Speaker 4: you know, for example, they've come with combination fixed combinations
- 43:26Speaker 4: or triple combinations to try to create alternas and opportunity.
- 43:30Speaker 4: But I want us to continue to see an ability
- 43:35Speaker 4: to get back to through innovation. And I think the
- 43:38Speaker 4: difference this time is going to be is even more
- 43:40Speaker 4: aggressive trade off. And we've got to find a way
- 43:42Speaker 4: to change potentially patent laws to provide more reward for
- 43:46Speaker 4: investment because the pharmacical industry is extremely, extremely risky business.
- 43:51Speaker 4: We put a lot of money up front with no
- 43:54Speaker 4: guarantee that we can even commercialize the product, cause we
- 43:56Speaker 4: do have a regulatory process for approval rightfully so, and
- 44:00Speaker 4: then we have to determine what the competitive set and
- 44:02Speaker 4: the dynamic between brand and generic and all those different
- 44:05Speaker 4: things and pay and what's covered not covered. So it's
- 44:07Speaker 4: a it's a risky business, but at the end of
- 44:09Speaker 4: the day, what we should be continuing to strive for
- 44:11Speaker 4: is our ability, which is what I think the spirit
- 44:14Speaker 4: of the industry has been is to create better products
- 44:18Speaker 4: that better serve. So one of the things I think
- 44:20Speaker 4: that's going to be important towards the portfolio expansion is
- 44:23Speaker 4: we have to we have to get away from just
- 44:27Speaker 4: making certain products a little bit better. We've got to
- 44:30Speaker 4: see some more differentiation. I mean, there's there's benefits in
- 44:33Speaker 4: doing that to a certain extent, but we're going to
- 44:34Speaker 4: have to find ways to create product. So it goes
- 44:37Speaker 4: back to my comment about in the past, I think
- 44:41Speaker 4: brand and geneeric, especially generic, it was all about how
- 44:44Speaker 4: many products you had and how big your portfolio is,
- 44:47Speaker 4: and how that portfolio could influence the system down in
- 44:50Speaker 4: the way to be successful. And I think it's no
- 44:52Speaker 4: longer than most marbles. I think it is the right marbles.
- 44:55Speaker 4: And I think when we do that, we're going to
- 44:58Speaker 4: find that pharmaceutical company can have a bigger portion of
- 45:02Speaker 4: their portfolio that is in a fair or appropriate margin
- 45:08Speaker 4: or profitability, and and that comes maybe there's some stabile stability,
- 45:12Speaker 4: and that stability can then work its way down and
- 45:14Speaker 4: maybe it's a concessions within the middle part of the
- 45:17Speaker 4: process and then that ultimately translates down to the pharmacy.
- 45:20Speaker 4: But at the end of the day, you know, we
- 45:22Speaker 4: we have to get back to a situation and everybody
- 45:26Speaker 4: has to have a hand in it that pharmacists that
- 45:28Speaker 4: if they dispense a product, they're not doing it at
- 45:31Speaker 4: a loss, and that the patient can get that product
- 45:36Speaker 4: at at a fair price and make sure that they
- 45:38Speaker 4: can be compliant with their with their medication. So a
- 45:42Speaker 4: lot of opportunity, but a lot of challenges to do that.
- 45:46Speaker 4: But because it's such an in the highly interdependent industry,
- 45:51Speaker 4: because we have so many people touching along the way
- 45:53Speaker 4: or influencing along the way, we've got to find a
- 45:56Speaker 4: way to do better. And I think it starts you know,
- 45:58Speaker 4: you know, I think they manufacturing industry actually has a
- 46:02Speaker 4: great opportunity to take a more aggressive lead in that
- 46:05Speaker 4: and help try to drive that. Instead of us kind
- 46:07Speaker 4: of sitting back and finding solutions or end to rounds
- 46:11Speaker 4: or things that we could do, We're going to have
- 46:12Speaker 4: to find, I think a more direct approach to change
- 46:15Speaker 4: some of the things to make us more successful. So Nick,
- 46:18Speaker 4: look at I couldn't have asked for a better person
- 46:20Speaker 4: to join me. It's a pleasure to have you on
- 46:23Speaker 4: the initial podcast of Executive Dose. I hope the people
- 46:27Speaker 4: that are listening will find this as an interesting platform,
- 46:31Speaker 4: and as we move forward, we will have an opportunity
- 46:34Speaker 4: to really dive into some very specific topics with a
- 46:39Speaker 4: great list of additional guests. And with that, I'm going
- 46:42Speaker 4: to actually turn it over Todd and he's going to
- 46:44Speaker 4: give you just a little preview of some of those
- 46:46Speaker 4: topics we think are going to be important over the
- 46:49Speaker 4: next the rest of the year.
- 46:50Speaker 3: I guess heck yeah, excited about this. The insights that
- 46:54Speaker 3: we're going to get from the Executive Dose is exactly
- 46:57Speaker 3: that we're going to be dialing into what's happening in
- 46:59Speaker 3: the We're going to be talking about the FDA. We're
- 47:02Speaker 3: going to be talking about, you know, becoming a leader
- 47:07Speaker 3: in how biosimilars are going to change our markets. We're
- 47:11Speaker 3: going to be talking about artificial intelligence and how the
- 47:15Speaker 3: pharmaceutical industry is primed to be impacted by the artificial
- 47:20Speaker 3: intelligence wave and how to get the most out of
- 47:24Speaker 3: that for development, drug development, and then of course ongoing
- 47:28Speaker 3: education I'm so excited Steven, that you're part of the
- 47:30Speaker 3: Pharmacy podcast Network now and that we have listeners that
- 47:34Speaker 3: are looking to jump in the car or take a
- 47:38Speaker 3: walk and listen to something that is very dialed in
- 47:42Speaker 3: to their specific sector of healthcare. And there's so much
- 47:45Speaker 3: going on. We look to leaders on this podcast network
- 47:50Speaker 3: to guide us and to give us a direction and insights.
- 47:53Speaker 3: So I want to say thank you to our first
- 47:55Speaker 3: guest on the Executive Dose, Nicholas Hart, CEO IBSA USA.
- 48:02Speaker 3: Thank you so much for being here with Steven and
- 48:04Speaker 3: I and Steven, this is going to be a lot
- 48:07Speaker 3: of fun, and I thank you so much for leading
- 48:10Speaker 3: us on the Executive Dose.
- 48:11Speaker 4: Well, thank you, And I'll just close by saying to
- 48:14Speaker 4: all you listening out there, the reason we're taking the
- 48:17Speaker 4: time to do this is because we want to create
- 48:20Speaker 4: a dialogue. We want to create a greater understanding and
- 48:24Speaker 4: less assumptions and how we all operate. Because by doing that,
- 48:29Speaker 4: I think we'll appreciate that we all ultimately have more
- 48:33Speaker 4: aligned goals than not. And I think when we do that,
- 48:38Speaker 4: we're going to find an opportunity, a rich opportunity to
- 48:43Speaker 4: explore and engage each other in a way that we
- 48:47Speaker 4: haven't in the past. We know the brand side. I've
- 48:49Speaker 4: worked on both the brand and generic side of my career,
- 48:52Speaker 4: and a lot of times we continue to do things
- 48:54Speaker 4: the same way. We might find new modalities of marketing
- 48:58Speaker 4: or sales, but we still kind of a tendency sometimes
- 49:01Speaker 4: to do the same thing, and that is we go
- 49:04Speaker 4: out and we investigate, and then we make determinations and
- 49:07Speaker 4: we execute, and sometimes that works really well, and sometimes
- 49:11Speaker 4: it completely missed the market. And I think that's what
- 49:13Speaker 4: is really the passion of why Executive Does came about,
- 49:17Speaker 4: is that if we can open up that dialogue and
- 49:20Speaker 4: everybody can see each other a little bit better, then
- 49:23Speaker 4: that Dia dogue is going to be a lot richer
- 49:25Speaker 4: and we're going to find even better solutions that everybody
- 49:28Speaker 4: will benefit. And as I always say, you know, we're
- 49:30Speaker 4: in this for the patient, and that's what we hope
- 49:34Speaker 4: to continue to create that kind of momentum and value
- 49:38Speaker 4: for the people that we serve.
- 49:40Speaker 3: And we'll be back. The Executive Dose will be returning
- 49:44Speaker 3: in June towards the end of the month, so be
- 49:46Speaker 3: on the lookout. Go subscribe on all of your favorite
- 49:50Speaker 3: podcast platforms, on Apple, on Spotify, anywhere you want to
- 49:53Speaker 3: listen to podcasts, you'll find the Executive Dose podcast. Thank
- 49:58Speaker 3: you for listening, Atta,